Research suggests that the CD30 antigen can be also recognized as a novel marker of neoplastic mastocytosis in advanced systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell leukemia (MCL) [37,38,39]. Here, TNFRSF8 is linked to aggressive systemic mastocytosis.